Bank of America just raised its EUR/USD forecast
Enovis Corporation (NYSE:ENOV), a company specializing in orthopedic and surgical appliances with annual revenue of $2.15 billion and a market capitalization of $1.86 billion, announced the results of its Annual Meeting of Stockholders held on Wednesday. According to InvestingPro analysis, the company currently shows signs of being undervalued, with a price-to-book ratio of 0.71x and strong gross profit margins of 60%. The meeting addressed the election of directors, ratification of the company’s independent auditor, and an advisory vote on executive compensation.
The stockholders elected nine directors to the board, each to serve until the next annual meeting or until their successors are elected. The directors were elected with a significant majority, with the number of votes cast for each ranging from approximately 49.6 million to 50.4 million. There were a notable number of broker non-votes for each director, indicating shares present at the meeting but not voted by brokers on behalf of shareholders. This comes at a time when InvestingPro data shows the company maintaining a healthy current ratio of 2.55, though operating with a significant debt burden. Discover 5 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report.
Additionally, the appointment of Ernst & Young LLP as Enovis’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with over 51.6 million votes in favor.
In an advisory capacity, the compensation of the named executive officers was approved with nearly 49.6 million votes for, 872,557 against, and 47,860 abstentions, accompanied by 1.7 million broker non-votes.
These results reflect the decisions made by the stockholders on the proposals as described in the Proxy Statement filed on April 11, 2025. The company filed this report in accordance with the Securities Exchange Act of 1934, as confirmed by Bradley J. Tandy, Senior Vice President and Chief Legal Officer of Enovis Corporation. The information is based on the company’s recent SEC filing.
In other recent news, Enovis Corporation reported its first-quarter 2025 financial results, surpassing analysts’ expectations with an adjusted earnings per share (EPS) of $0.81, compared to the forecast of $0.74. The company achieved revenue of $559 million, marking an 8% year-over-year increase, although it slightly missed the forecast of $558.9 million. Despite the positive earnings surprise, the stock experienced a decline. Additionally, Enovis saw a double-digit sales increase of 10% when adjusted for foreign exchange effects and expanded its gross margin by 300 basis points year-over-year. Analyst David Turkaly from JMP Securities adjusted Enovis’s stock price target to $55.00 from $62.00, maintaining a Market Outperform rating. Canaccord Genuity also revised Enovis’s price target, reducing it from $75.00 to $70.00, while continuing to endorse the stock with a Buy rating. These developments reflect a more conservative valuation approach in light of current market conditions and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.